Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Lilly (Eli) & Co. (NY: LLY)
59.87 USD  -0.16 (-0.27%)
Streaming Delayed Price  /  Updated: 1:09 PM EDT, Apr 23, 2014  /  Add to My Watchlist      
(LLY) Community Analysis from
April 23, 2014
(Jutia Group, 4/21/14)
[Reuters] - U.S. health regulators on Monday approved an Eli Lilly and Co drug to treat advanced stomach cancer and a form of cancer in the area where the esophagus...(read more)
(Jutia Group, 4/1/14)
[PR Newswire] - CINCINNATI, April 1, 2014 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and...(read more)
(Stock Blog Hub, 5/3/13)
Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary...(read more)
Eli Lilly and Company (LLY) Company Overview

There is no analysis for LLY yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here